EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania

Doreen Kamori iD, Godfrey Barabona, Werner Maokola, Joan Rugemalila, Macdonald Mahiti, Mucho Mizinduko, Amon Sabasaba, George Ruhago iD, Linda Mlunde, Salim S Masoud, Davis Amani, Erick Mboya und 9 weitere

PLOS ONE · 14.08.2024 · 19 (8) · e0307003

DOI: 10.1371/journal.pone.0307003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 14.08.2024. Verfasst von Doreen Kamori und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Pyridones, HIV Infections, Oxazines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, Global Fund to Fight AIDS, Tuberculosis and Malaria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tanzania has made significant progress in improving access to HIV care and treatment. However, virologic suppression among people living with HIV (PLHIV) has not been fully realized. In March 2019, Tanzania introduced a World Health Organization (WHO)—recommended dolutegravir-based regimen as the default first-line regimen. Eighteen months later we investigated the HIV viral suppression rates and the factors associated with lack of viral suppression among PLHIV (children and adults) in Tanzania. Methodology A cross-sectional survey was conducted from September to December 2020 among PLHIV on antiretroviral therapy (ART) in Tanzania. Whole blood samples, demographic data and clinical information were obtained from eligible adults (≥15 years) and children (< 15 years) attending thirty-six HIV care and treatment centres located in 22 regions of Tanzania mainland. A whole blood sample from each participant was processed into plasma and HIV viral load was estimated using real-time PCR. HIV viral suppression was defined at a cut-off of < 50 copies/mL as recommended by WHO. Analyses were conducted using descriptive statistics to establish the national representative prevalence of viral suppression, and logistic regression analyses to determine independent factors associated with non-suppression.

Results

A total of 2,039 PLHIV on ART were recruited; of these, adults and children were 57.5% (n = 1173) and 42.5% (n = 866), respectively. Among the adult population, the mean age and standard deviation (SD) was 42.1 ± 12.4 years, with 64.7% being female. Among children, the mean age and SD were 9.6 ± 3 years, and 53.2% were female. Overall viral suppression at < 50 copies/mL (undetectable) was achieved in 87.8% of adults and 74.4% of children. Adults and children on dolutegravir-based regimen recorded viral suppression rates of 89.7% and 85.1% respectively. Factors independently associated with lack of viral suppression status in the adult population were age and ART adherence while in the children population, the factors were sex, ART adherence, and current ART regimen (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingPyridonesHIV InfectionsOxazinesPiperazinesViral LoadHumansFemaleTanzaniaMaleAdultChildAdolescentCross-Sectional StudiesMiddle AgedYoung AdultChild, PreschoolHIV Integrase InhibitorsAnti-HIV AgentsHIV-1Dolutegravir

Substanzen

Heterocyclic Compounds, 3-RingPyridonesOxazinesPiperazinesHIV Integrase InhibitorsAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • National AIDS Control Programme, Dodoma, Tanzania.
  • Department of Internal Medicine, Muhimbili National Hospital, Dar es Salaam, Tanzania.
  • Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

ORCID-Profile: Doreen Kamori, George Ruhago, Takamasa Ueno

Förderung

  • FIC NIH HHS
  • Global Fund to Fight AIDS, Tuberculosis and Malaria

Zitieren

APA

Kamori, D., Barabona, G., Maokola, W., Rugemalila, J., Mahiti, M., Mizinduko, M., Sabasaba, A., Ruhago, G., Mlunde, L., Masoud, S. S., Amani, D., Mboya, E., Mugusi, S., Rwebembera, A., Mgomella, G., Asiimwe, S., Mutayoba, B., Njau, P., Ueno, T., …, & Sunguya, B. (2024). HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania. PLOS ONE, 19(8), e0307003. https://doi.org/10.1371/journal.pone.0307003

Vancouver

Kamori D, Barabona G, Maokola W, Rugemalila J, Mahiti M, Mizinduko M, et al. HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania. PLOS ONE. 2024;19(8):e0307003. doi:10.1371/journal.pone.0307003

BibTeX
@article{Kamori2024,
  author = {Kamori, Doreen and Barabona, Godfrey and Maokola, Werner and Rugemalila, Joan and Mahiti, Macdonald and Mizinduko, Mucho and Sabasaba, Amon and Ruhago, George and Mlunde, Linda and Masoud, Salim S and Amani, Davis and Mboya, Erick and Mugusi, Sabina and Rwebembera, Anath and Mgomella, George and Asiimwe, Sarah and Mutayoba, Beatrice and Njau, Prosper and Ueno, Takamasa and Pembe, Andrea and Sunguya, Bruno},
  title = {HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {8},
  pages = {e0307003},
  doi = {10.1371/journal.pone.0307003}
}
Kostenlos starten →